Kyntra Bio Nasdaq/NYSE Compliance Notice
Kyntra Bio received a delisting determination from Nasdaq on September 30, 2026, for failing to meet the minimum total assets and revenue requirements under Listing Rule 5450(b). The company has requested a hearing before a Nasdaq Hearings Panel to seek an extension, which stays the suspension of its common stock pending a decision. Kyntra Bio is preparing a compliance plan but cannot guarantee the Panel will grant the request for continued listing.
- Counterparty
- Nasdaq
- Term
- 180 days